Iovance Biotherapeutics (NASDAQ:IOVA) Announces Quarterly Earnings Results

Iovance Biotherapeutics (NASDAQ:IOVA) posted its earnings results on Thursday. The biotechnology company reported ($0.26) EPS for the quarter, hitting the consensus estimate of ($0.26), Zacks reports. The firm had revenue of $73.69 million for the quarter, compared to the consensus estimate of $72.17 million. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. Iovance Biotherapeutics updated its FY 2025 guidance to EPS.

Iovance Biotherapeutics Stock Performance

Shares of NASDAQ:IOVA opened at $4.24 on Friday. The company has a market cap of $1.29 billion, a P/E ratio of -2.85 and a beta of 0.53. The stock’s 50-day moving average is $6.27 and its 200-day moving average is $8.62. Iovance Biotherapeutics has a 52-week low of $3.62 and a 52-week high of $18.24.

Wall Street Analyst Weigh In

Several equities analysts have commented on IOVA shares. HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of Iovance Biotherapeutics in a research report on Friday. Piper Sandler lowered their target price on shares of Iovance Biotherapeutics from $7.50 to $6.00 and set a “neutral” rating on the stock in a research report on Friday. Finally, Robert W. Baird lowered their target price on shares of Iovance Biotherapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Friday. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $20.50.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.